New Horizon Health Ltd. (6606)

Overview

New Horizon Health Limited stands out as an investment holding entity deeply engaged in the innovation and development of cancer screening products focused on addressing colorectal, cervical, and various other cancers within the People's Republic of China. Since its establishment in 2015, with its headquarters located in Hangzhou, China, the company has committed itself to pushing the boundaries of medical diagnostics technology. Beyond its primary research and development operations, New Horizon Health Limited broadens its scope to include the provision of technical services, consultancy, and technology transfers. Additionally, it delivers medical services alongside engaging in the manufacturing and sales of medical and laboratory equipment, particularly fecal occult blood test kits. Notably, the company not only caters to domestic needs but also partakes in technological imports and exports, showcasing its global outlook in the medical diagnostics and equipment sector.

Products and Services

At the core of New Horizon Health Limited's offering lies a suite of innovative cancer screening products and medical services, designed to meet the varied needs of patients and healthcare providers alike:

• ColoClear: Positioned as an early screening product for colon cancer, ColoClear exemplifies the company's pursuit of early detection solutions. This product allows for an efficient and non-invasive approach to identifying potential colon cancer markers, underscoring the company's commitment to advancing cancer diagnostics.
• Pupu Tube: A self-administered fecal occult blood test product, the Pupu Tube is part of New Horizon Health Limited’s suite designed to simplify and encourage regular screening practices among individuals. Its user-friendly approach facilitates early detection of hidden blood in stool, which can be an early indicator of colorectal cancer.
• UU Tube: Addressing the need for early detection of Helicobacter pylori, a bacteria linked to peptic ulcers and an increased risk of stomach cancer, the UU Tube is a self-test product allowing individuals to take proactive steps towards their gastrointestinal health.

In addition to these groundbreaking products, New Horizon Health Limited is also deeply immersed in the continuous research and development of medical diagnostic technologies. This involves not just the creation of new products, but also the provision of essential technical services, consultancy, and technology transfers that are crucial for the advancement of medical diagnostics. Alongside, the company offers medical services, further showcasing its comprehensive approach to cancer detection and diagnostics. Its engagement in the manufacturing and sales of laboratory equipment and fecal occult blood test kits, coupled with its active participation in technological imports and exports, paints a picture of a company that is as innovative as it is expansive in its offerings.